WADA classifies it as one. The Russian literature describes it as an actoprotector that raises dopamine synthesis rather than blocking reuptake, which would make it behave unlike a conventional stimulant. Those two framings coexist and only one of them is enforced at a doping control.

How long does it stay detectable?

Longer than most people expect, because the half-life is long and it accumulates with repeated dosing. Stopping a few days before a test is not a plan.

No. It is an adamantane derivative, related to amantadine, and it appears alongside peptides only because of where it is sold.

Anti-aging & longevity

Bromantane

Ladasten · ADK-709 · N-(2-adamantyl)-N-(para-bromophenyl)amine

Approved for another indicationProhibited in sportReviewed 18 Aug 2026

Bromantane is not a peptide. It is an adamantane derivative, chemically related to amantadine, developed in the Soviet Union and registered in Russia as Ladasten for asthenia, the persistent fatigue that follows illness or prolonged stress.

It is described as an actoprotector, a Soviet drug category with no Western equivalent: something that improves physical and mental performance under stress without the stimulant profile that usually implies. The claim is that it raises dopamine by increasing synthesis rather than by blocking reuptake, which if true would explain why it is not described as producing the crash or dependence a stimulant does.

Its most verifiable fact is a doping one. Bromantane produced positive tests at the 1996 Atlanta Olympics, and it is on the WADA prohibited list. Anyone subject to testing should treat that as the operative information about this compound rather than anything else on this page.

How it works

Bromantane is reported to increase dopamine synthesis by upregulating tyrosine hydroxylase, the rate-limiting enzyme in the pathway, rather than by blocking reuptake as stimulants do. More dopamine made, rather than more dopamine left in the synapse.

That distinction is the basis of the claim that it does not produce tolerance, crash or dependence in the way conventional stimulants do. The evidence for the claim is Russian and has not been independently reproduced.

It also has documented anxiolytic activity, and the Russian literature describes it as combining stimulant and anxiolytic effects. An unusual pairing, and one reason it attracts attention.

It has a long half-life and accumulates with repeated dosing, which is relevant to both the effect and the length of time it remains detectable.

Quick reference

Commonly described dose: 50 mg–100 mg
How often: 50 to 100 mg daily, in courses of 2 to 4 weeks
Route: Oral
Timing: Morning, in the registered protocol. Later dosing disturbs sleep, and the long half-life makes that harder to undo.
Storage once mixed: Not applicable — this is taken orally
Cycle: 2 to 4 weeks on, At least a month between courses off

These describe what sources report, not what you should do. Full detail and provenance in the dosing section below.

Price index

Per-milligram pricing across vendors arrives with the directory. We are recording prices now so the history exists when the page ships.

Vocabulary on this page

Half-life: The time it takes for half of a compound to be cleared from the body.
Peptide: A short chain of amino acids: the same building blocks as a protein, in a chain short enough to behave differently.

The whole glossary →

Regulatory status — Russia and United States

Registered in Russia as Ladasten for asthenic conditions. Not approved in the United States or the European Union, and prohibited in sport by the World Anti-Doping Agency following positive tests at the 1996 Olympics.

Last reviewed 18 Aug 2026. Regulatory positions in this category change frequently; we date this line so you can see how current it is.

What it is studied for

Each entry states the evidence behind it. We do not rank indications by effectiveness — for most compounds here, that would be a claim nobody can support.

Asthenia

Published review

The registered Russian indication.

EvidenceRussian clinical work supporting registration as Ladasten for asthenic conditions. Not replicated outside that programme.

Fatigue, focus and physical performance

Community practice

Why it is bought elsewhere, and why it is banned in sport.

EvidenceThe performance claim is taken seriously enough by anti-doping authorities to prohibit it. No Western trial supports its use in healthy people.

Identity and clearance

Molecule

Class: Adamantane derivative: a small molecule, not a peptide
Molecular weight: 346.3 Da

Chemically related to amantadine. Taken orally.

Dose protocols reported in sources

Displayed for reference only. Every row says where it came from, and a trial protocol and a community convention are not the same kind of information. None of this is fed into the calculator, and none of it is a recommendation.

Dose protocols reported in sources, with the source of each.
Goal	Dose	Frequency	Route	Units, 50 mg vial	Source	Start this protocol
Registered Russian dosing	50 mg – 100 mg	50 to 100 mg daily, in courses of 2 to 4 weeks	OralDoses here are tens of milligrams, not micrograms. The registered protocol is a short course, and the long half-life means levels accumulate across it.	from 100 u	Published review	Start this

Start this copies a row into a protocol of your own, which you can then edit. Where a source gave a dose range or an ambiguous frequency, those fields arrive empty — we will not pick a number on your behalf.

Cycling

Published review

2 to 4 weeks on, At least a month between courses off.

From the registered Russian protocol. The accumulation across a course is part of why it is structured that way.

Safety

Reported effects

Disturbed sleepCommunity practice
Commonly reported
Compounded by the long half-life. A dose taken too late is not fixed by skipping the next one.
Headache and dry mouthPublished review
Reported in the Russian literature
Accumulation with continued usePublished review
Expected from its pharmacokinetics
The long half-life means the effect in week three is not the effect in week one. This is why the registered use is a short course.
Long-term effects on dopamine signallingPublished review
Unknown
A compound that raises dopamine synthesis over months has an obvious question attached to it that no study has answered.

When to stop

Sleep disturbance that does not settle.
Agitation, anxiety or mood change.
Persistent headache.
Any allergic response: rash, hives, facial swelling or difficulty breathing. Seek urgent care.

Interactions and situations that need care

Competing in a tested sportAvoid
Prohibited in competition by WADA as a stimulant, added after positive tests at the 1996 Olympics. Its long half-life means it stays detectable well beyond the last dose, so stopping shortly before a competition does not help.
Any psychiatric condition, or dopaminergic medicationAvoid
Raising dopamine synthesis in someone taking a drug that acts on the same system — or living with a condition sensitive to it — is an interaction nobody has characterised.
Pregnancy and breastfeedingAvoid
No reproductive or developmental safety data.
Continuous useUse caution
It accumulates. The registered protocol is a two to four week course for that reason, and nothing establishes what continuous dosing does.

SportProhibited by the World Anti-Doping Agency under S6: Stimulants, in competition. Added following positive tests at the 1996 Atlanta Olympics. Its long half-life means it remains detectable well after the last dose.

What to expect

It is prohibited in competition by WADA, and it has a long half-life. If you are tested, that is the only fact on this page that matters.
It is not a peptide. It is an adamantane derivative, chemically closer to amantadine.
Registered in Russia for asthenia, unapproved in the US and EU.
The claim that it raises dopamine without stimulant tolerance is interesting and unreplicated outside Russia.
It accumulates across a course, so the effect is not stable from week to week.

Storage and handling

Freeze-dried powder: Tablets or powder at room temperature, dry and out of light.
After mixing: Not applicable — this is taken orally.

Printable one-pager How to reconstitute a vial, step by step

Checking your vial

Research chemicals carry no manufacturing standard, so what the vial looks like is often the only quality signal available before you use it. More on assessing quality and COAs.

You cannot assess a powder by looking at it
Third-party testing is the only verification available, and this is a compound where identity matters legally as well as pharmacologically.

Questions

Is it a stimulant?: WADA classifies it as one. The Russian literature describes it as an actoprotector that raises dopamine synthesis rather than blocking reuptake, which would make it behave unlike a conventional stimulant. Those two framings coexist and only one of them is enforced at a doping control.
How long does it stay detectable?: Longer than most people expect, because the half-life is long and it accumulates with repeated dosing. Stopping a few days before a test is not a plan.
Is it a peptide?: No. It is an adamantane derivative, related to amantadine, and it appears alongside peptides only because of where it is sold.

References

Russian clinical literature on regulatory peptides and nootropics: scope and limits
Russian pharmacology and psychiatry literature, 2015 · Body of clinical work, largely unregistered and not blinded to contemporary standards
Humans
Reports anxiolytic, nootropic and neuroprotective effects supporting registration of several of these compounds in Russia. Methodology, reporting standards and the absence of independent replication limit how much weight the findings carry elsewhere.
Commonly reported community protocols
Bioalmanac editorial summary of public community sources, 2026 · Not a study
Records dose and route patterns described in public discussion. Carries no evidential weight about safety or effect.

Related compounds

GHK-Cu

A naturally occurring copper-binding tripeptide with a long history in topical skincare research. Injected use is not what the research studied.

Ipamorelin

A selective growth hormone secretagogue that prompts a short pulse of GH release. Widely used, and supported almost entirely by early pharmacology rather than outcome trials.

CJC-1295

A GHRH analogue that raises growth hormone by amplifying the body's own release signal. Sold in two forms whose durations differ by two orders of magnitude.

Tesamorelin

A GHRH analogue approved by the FDA for reducing excess visceral fat in HIV-associated lipodystrophy. The only compound in this category with completed phase 3 trials.

Keep this page honest

If something here is wrong, out of date, or missing a source, tell us and we will fix it and say that we did.

Suggest a correction

This page is educational. It describes what published research reports, not what you should do. Peptides discussed here are largely not approved for human use, and nothing on Bioalmanac is medical advice. No clinician reviews these pages.

Page last updated 18 Aug 2026